{"id":102288,"date":"2020-02-13T04:42:22","date_gmt":"2020-02-13T12:42:22","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2020\/02\/utilizing-biopharma-4-0-to-boost-coronavirus-2019-ncov-vaccine-efforts"},"modified":"2020-02-13T04:42:22","modified_gmt":"2020-02-13T12:42:22","slug":"utilizing-biopharma-4-0-to-boost-coronavirus-2019-ncov-vaccine-efforts","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2020\/02\/utilizing-biopharma-4-0-to-boost-coronavirus-2019-ncov-vaccine-efforts","title":{"rendered":"Utilizing Biopharma 4.0 to Boost Coronavirus 2019-nCoV Vaccine Efforts"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/utilizing-biopharma-4-0-to-boost-coronavirus-2019-ncov-vaccine-efforts3.jpg\"><\/a><\/p>\n<p>Scientists are scrambling to develop a vaccine against coronavirus 2019-nCoV and plan to use advanced bioprocessing methods and techniques to accelerate production.<\/p>\n<p>#coronavirus #vaccine #bioprocessing<\/p>\n<hr>\n<p>At present there is no vaccine against the coronavirus However, various groups have started working on them, including <a href=\"https:\/\/www.jnj.com\/johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat\">Johnson &amp; Johnson<\/a> (J&amp;J).<\/p>\n<p>Sarah Smith, senior manager, communications &amp; public affairs, EMEA at J&amp;J\u2019s Janssen unit, tells <em>GEN <\/em>that, \u201cWe began working on a vaccine two weeks ago, when the viral sequence became publicly available, and are hopeful that we can create a candidate vaccine for this virus and can start a Phase I clinical study within approximately 8\u201312 months. If necessary, we will work to scale up production of a suitable vaccine candidate in parallel. While it is possible that the virus could disappear relatively fast, we started the work quickly because we want to be prepared.\u201d<\/p>\n<p>Development and production will leverage Janssen\u2019s AdVac vector technology and PER.C6 manufacturing platform, which were previously used to make an investigational Ebola vaccine, currently deployed in the <a href=\"https:\/\/www.jnj.com\/johnson-johnson-announces-donation-of-up-to-500-000-regimens-of-janssens-investigational-ebola-vaccine-to-support-outbreak-response-in-democratic-republic-of-the-congo-drc\">Democratic Republic of the Congo<\/a> and <a href=\"https:\/\/www.jnj.com\/johnson-johnson-announces-donation-of-up-to-500-000-regimens-of-janssens-investigational-ebola-vaccine-to-support-outbreak-response-in-democratic-republic-of-the-congo-drc\">Rwanda<\/a>. According to Smith, \u201cWe will use single-use technology in order to produce larger quantities of the vaccine on a flexible schedule at a later moment in time.\u201d She also says that most manufacturing would be carried out in house, adding that \u201cfor fill\/finish activities, we will utilize external CMOs.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Scientists are scrambling to develop a vaccine against coronavirus 2019-nCoV and plan to use advanced bioprocessing methods and techniques to accelerate production. #coronavirus #vaccine #bioprocessing At present there is no vaccine against the coronavirus However, various groups have started working on them, including Johnson &amp; Johnson (J&amp;J). Sarah Smith, senior manager, communications &amp; public affairs, [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-102288","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/102288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=102288"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/102288\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=102288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=102288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=102288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}